Clinical Trial

Efficacy and Safety of Xiangjurupining Capsule for Hyperplasia of Mammary Glands

Name: Efficacy and Safety of Xiangjurupining Capsule for Hyperplasia of Mammary Glands — clinical trial record (NCT06685978)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 3

View on ClinicalTrials.gov →

Record status

This record was last updated November 13, 2024 (before its estimated April 30, 2026 completion). Its status may not reflect the trial's current state.

Summary

This study will evaluate the efficacy and Safety of Xiangjurupining Capsule in the treatment of Hyperplasia of Mammary Glands(stagnation of liver-qi and phlegm).

Trial Details

NCT Number	NCT06685978
Lead Sponsor	Tasly Pharmaceutical Group Co., Ltd
Conditions	Hyperplasia of Mammary Glands
Enrollment	430 participants
Start Date	2024-04-26
Primary Completion	2026-04-30 (estimated)
Study Completion	2026-07-31 (estimated)
Updated on ClinicalTrials.gov	2024-11-13